Heart failure drug aims to boost daily living and cut hospital visits

NCT ID NCT07697833

Not yet recruiting Disease control Sponsor: National Institute of Cardiovascular Diseases, Pakistan Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates whether vericiguat, added to standard treatment, can improve quality of life and reduce hospitalizations in adults with heart failure and reduced ejection fraction. Participants receive either vericiguat or a placebo for six months, and their health status is measured using a heart failure questionnaire. The study includes 500 people with chronic heart failure and elevated natriuretic peptide levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vericiguat
What this could lead to: If it works, this could offer a new treatment option to improve daily life and reduce hospital stays for people with heart failure.
What could go wrong: This is a phase 4 trial, so vericiguat is already approved; however, it may not show meaningful benefit over standard care, and side effects like low blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.